Can I read Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort on EtoBox?

Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort by Simon Baldacci; Benjamin Besse; Virginie Avrillon; Bertrand Mennecier; Julien Mazieres; Pascale Dubray-Longeras; Alexis B. Cortot; Renaud Descourt; Helene Doubre; Xavier Quantin; Michael Duruisseaux; Isabelle Monnet; Denis Moro-Sibilot; Jacques Cadranel; Christelle Clément-Duchêne; Sophie Cousin; Charles Ricordel; Patrick Merle; Josiane Otto; Sophie Schneider; Alexandra Langlais; Franck Morin; Virginie Westeel; Nicolas Girard is a Medicine article available to read on EtoBox.

What is Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort about?

## Background: Anaplastic lymphoma kinase (alk)-rearranged (alk+) non-small cell lung cancer (nsclc) represents a rare subset of lung cancer, with specific presentation, and multiple treatment options, including selective tyrosine kinase inhibitors (tkis). real-world evidence is insufficient regarding the actual real-life treatment sequences in the late line setting, and available clinical trials may not reflect real-world situation. here, we took advantage of the french expanded access program (eap) of lorlatinib, a third-generation tki targeting alk and ros1, to assess treatment sequencing, and lorlatinib efficacy and safety, in patients with alk+ nsclc. ## Methods: All consecutive patients with advanced alk+ nsclc treated between october 2015 and june 2019 with lorlatinib as part of eap were included. data were collected and reviewed from medical records by independent research staff of the french thoracic cancer intergroup. the primary endpoint was progression-free survival (pfs). ## Results: Of the 208 patients included, 117 (56%) were female, 142 (69%) were never smokers, and 180 (87%) had stage iv nsclc at diagnosis. the most frequent histology was adenocarcinoma (94%), and

Who reads Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort?

Author

Simon Baldacci; Benjamin Besse; Virginie Avrillon; Bertrand Mennecier; Julien Mazieres; Pascale Dubray-Longeras; Alexis B. Cortot; Renaud Descourt; Helene Doubre; Xavier Quantin; Michael Duruisseaux; Isabelle Monnet; Denis Moro-Sibilot; Jacques Cadranel; Christelle Clément-Duchêne; Sophie Cousin; Charles Ricordel; Patrick Merle; Josiane Otto; Sophie Schneider; Alexandra Langlais; Franck Morin; Virginie Westeel; Nicolas Girard

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Health Sciences)